{"filings":[{"id":1580441,"accession_number":"0001493152-26-032830","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2026-07-10T20:01:30+00:00","items":["3.01","9.01"],"status":"ready","headline":"ENvue Medical receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days (May 26–July 8, 2026).","Ineligible for 180-day cure period due to reverse stock split (1-for-10) on Aug 12, 2025.","Company will request a hearing before Nasdaq Panel to appeal the determination.","No assurance that continued listing will be granted or compliance regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-10","daily_digest_url":"/daily/2026-07-10","daily_digest_rank":2},{"id":102753,"accession_number":"0001493152-26-005555","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ENvue Medical amends CEO equity plan, appoints David Johnson as Chairman with 3.5% RSU grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendment changes CEO Doron Besser's equity grants from annual to quarterly, with prorated gross-up on termination without cause.","David Johnson appointed Chairman; receives $10k/month and RSUs representing 3.5% of fully diluted common stock.","Chairman's RSUs vest over 2 years with anti-dilution protection; agreement auto-renews annually unless terminated.","Besser's initial RSU grant remains 9% of fully diluted shares, subject to Israeli Tax Authority approval.","Both agreements effective February 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102752,"accession_number":"0001493152-26-004523","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"ENvue Medical removes Series H Preferred Floor Price in exchange for $2.5M investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Amendment Agreement with Required Holders to file Certificate of Amendment removing Floor Price from Series H Convertible Preferred Stock.","In consideration, holders exercised $2,500,000 of Additional Investment Right from July 2025 purchase agreement.","Certificate of Amendment filed and effective January 30, 2026.","The amendment modifies conversion rights of Series H Preferred by eliminating the Floor Price.","Company receives $2.5M new capital from existing preferred holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118984,"accession_number":"0001493152-25-029482","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ENvue Medical amends 2024 Long Term Incentive Plan for Israeli tax compliance and name change","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended and restated 2024 Long Term Incentive Plan on December 24, 2025.","Adds restricted stock units under Section 102 for Israeli tax compliance; other non-material updates.","Reflects company name change from NanoVibronix to ENvue Medical and prior stockholder-approved amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118983,"accession_number":"0001493152-25-029018","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NanoVibronix amends CEO contract with 9% equity grant; appoints interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Doron Besser new base salary $360K, bonus up to $180K; severance of 12 months' base salary on change-of-control termination.","Besser receives 180,000 RSUs (9% of outstanding common stock) plus annual grants to maintain 9% equity.","CFO Stephen Brown departed Dec. 18, 2025; Nicole Fernandez-McGovern appointed Interim CFO via consulting agreement with RCM Financial Consulting.","Fernandez-McGovern receives $300K annual salary; served as CFO of NLS Pharmaceutics and interim CFO of Hayden AI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118988,"accession_number":"0001493152-25-027380","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"NanoVibronix changes name to ENvue Medical, ticker to FEED effective Dec 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Dec 12, 2025, NanoVibronix changed name to ENvue Medical, Inc. and ticker symbol from NAOV to FEED on Nasdaq.","CEO Doron Besser said rebranding reflects new strategic direction focused on ENvue feeding-tube placement system.","Company aims to scale hospital utilization and build enteral-feeding ecosystem via internal and external development.","No stockholder action required; CUSIP unchanged; existing shares unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118987,"accession_number":"0001493152-25-026247","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NanoVibronix board reconstituted; four directors retire, five new directors elected, LTIP share pool expanded","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Christopher Fashek, Thomas Mika, Martin Goldstein, Brian Murphy retired immediately before the 2025 Annual Meeting for personal reasons; no disagreement with Company.","Stockholders elected Doron Besser, David Johnson, Zeev Rotstein, Nino Pionati, Alison Geiger Burgett as directors for one-year terms.","First Amendment to 2024 Long-Term Incentive Plan approved; shares reserved increased by 1,200,000 to 1,205,454 shares.","Share issuance proposal under Nasdaq Rule 5635(d) approved, covering convertible preferred stock and warrants from July 2025 private placement.","Kost Forer Gabbay & Kasierer (EY) ratified as independent auditor for FY 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118986,"accession_number":"0001493152-25-024167","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"NanoVibronix to rebrand as ENvue Medical, focus on enteral-feeding navigation platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ENvue feeding-tube placement system identified as core growth platform; 38 hospitals already using it.","U.S. enteral-feeding devices market projected at ~$1.8B by 2030; ENvue is 510(k)-cleared for adults.","Company planning name change to ENvue Medical and new NASDAQ ticker symbol.","Exploring strategic alternatives (partnerships/divestitures) for legacy PainShield and UroShield technologies.","CEO Doron Besser (appointed June 2025) outlines multi-phase roadmap including pediatric, imaging, and vascular applications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118985,"accession_number":"0001493152-25-020214","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoVibronix announces four directors will not stand for reelection at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Fashek, Thomas Mika, Martin Goldstein, and Brian Murphy to retire from Board immediately prior to 2025 Annual Meeting.","Fashek served on Audit, Nominating, and Compensation Committees; Mika on Audit and Compensation; Goldstein on Nominating.","Departures are for personal reasons and do not result from any disagreement with the Company.","No replacements for the departing directors have been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135530,"accession_number":"0001493152-25-013881","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"NanoVibronix prices $2M registered direct offering of common stock and prefunded warrants at $7.01","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 74,114 common shares and prefunded warrants for 217,090 shares at $7.01 per share (or $7.009 per warrant).","Gross proceeds of ~$2.0M; net proceeds ~$1.8M after placement fees and expenses.","Proceeds to be used for working capital, repayment of debt and/or redemption of preferred stock.","Palladium Capital Group acted as exclusive placement agent; closing expected September 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135529,"accession_number":"0001641172-25-023995","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"NanoVibronix dismisses Zwick CPA, appoints E&Y as auditor; CFO Brown gets amended deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Zwick CPA PLLC; new auditor is Kost Forer Gabbay & Kasierer (E&Y) for FY2025.","Zwick's reports included a going-concern explanatory paragraph; material weaknesses in internal controls identified.","CFO Stephen Brown entered amended employment agreement with $300K annual salary, effective Aug 11, 2025.","Severance of $180K if terminated without cause or resignation after 6-month anniversary, conditional on release and reaudited financials.","Audit committee approved changes; no disagreements with Zwick on accounting principles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135528,"accession_number":"0001641172-25-022751","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"NanoVibronix effects 1-for-10 reverse stock split effective Aug 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split reduces outstanding shares from 7,968,868 to ~796,887.","Effective 4:05 p.m. ET on Aug 11, 2025; split-adjusted trading begins Aug 12, 2025.","No fractional shares issued; any fractional shares rounded up to whole number.","Adjustments made to equity awards, warrants, and convertible securities proportionally.","New CUSIP 63008J884; trading symbol remains NAOV on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135527,"accession_number":"0001641172-25-021544","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoVibronix appoints Rita Silberberg as EVP Finance, CAO and Corporate Secretary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective July 24, 2025; Silberberg also named Corporate Secretary same day.","Silberberg brings 15+ years experience; prior CFO at Gravity Creative Space and Director at Ernst & Young.","Employment agreement provides starting salary of NIS 44,000/month, rising to NIS 68,750/month upon milestones.","No family relationships or related-party transactions disclosed per Reg S-K Items 401(d) and 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135526,"accession_number":"0001641172-25-020569","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","5.03"],"status":"ready","headline":"NanoVibronix raises $8M in private placement of Series H convertible preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of $8M gross proceeds: 8,889 Series H preferred shares ($1,000 stated value, convertible at $1.01/sh) and warrants for 4,678,363 shares at $2.25/sh.","Second closing of $2.22M (2,222 preferred shares) contingent on customary conditions.","Net proceeds: $5M to redeem Series X preferred stock; remainder for working capital.","Investor gets right to buy up to $44M additional preferred stock over 36 months at 85% of average VWAP.","Company must seek stockholder approval for issuance exceeding 19.99% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135525,"accession_number":"0001641172-25-020209","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoVibronix shareholders approve reverse stock split with 1:2 to 1:50 range","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment approved: ratio of 1-for-2 to 1-for-50, at Board discretion, within one year.","Votes: 550,179 for, 183,224 against, 33,836 abstentions.","Adjournment proposal approved (573,509 for, 166,066 against) but not needed.","Special meeting held July 17, 2025; previously adjourned from July 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135524,"accession_number":"0001641172-25-018809","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NanoVibronix special meeting adjourned due to lack of quorum; reconvened July 17","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting opened and adjourned without any business due to absence of quorum.","Reconvened virtually on Thursday, July 17, 2025 at 10:00 a.m. Eastern Time.","Record date for voting remains May 16, 2025 unchanged.","Proxy deadline extended to 11:59 p.m. ET on July 16, 2025; previously submitted proxies remain valid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135523,"accession_number":"0001641172-25-018400","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"NanoVibronix corrects typo in Series G preferred stock Floor Price to $1.91","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrected definition of Floor Price from $1.02 to $1.91 in Series G Preferred Stock Certificate of Designation.","Certificate of Correction filed with Delaware Secretary of State on July 8, 2025.","All other terms of Series G Preferred Stock remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152521,"accession_number":"0001641172-25-013620","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"NanoVibronix appoints Doron Besser as CEO; Brian Murphy retires but stays on board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Murphy retired as CEO of NanoVibronix effective June 4, 2025, and will remain as a director.","Doron Besser, previously CEO of subsidiary ENvue Medical Holdings, appointed as CEO effective same date.","NanoVibronix completed acquisition of ENvue on February 14, 2025, creating a combined growth platform.","Besser has a medical device background; previously helped lead superDimension, acquired by Covidien for ~$300M.","Board Chairman Christopher Fashek thanked Murphy and expressed confidence in Besser's leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152520,"accession_number":"0001641172-25-011246","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"NanoVibronix raises $10M in public offering of Series G preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from 400,000 Series G convertible preferred shares at $25/share, each with a warrant to buy 4.9M common shares at $2.04.","Preferred pays 9% cumulative dividend, convertible at $2.04/share, subject to full-ratchet anti-dilution and 4.99%/9.99% beneficial ownership cap.","Use of proceeds: repay $1.3M debenture (Feb 2025) and up to $700k on $2.5M note (Jan 2025); remainder for general corporate purposes.","Amended Series X preferred: increased authorized shares from 57,720 to 62,220 and cut conversion price to match Series G price.","Dawson James Securities acted as sole bookrunner; offering closed May 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152519,"accession_number":"0001641172-25-003717","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"NanoVibronix subsidiary issues $360K note; Nasdaq confirms compliance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["ENvue Medical Holdings issued $360K promissory note to Alpha Capital Anstalt, 8% interest, maturity June 11, 2025.","NanoVibronix fully guarantees subsidiary's obligations under the note.","Nasdaq confirmed company regained minimum bid price and equity compliance; subject to one-year mandatory panel monitor.","If non-compliance during monitoring, no plan permitted; delist determination will be issued immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152518,"accession_number":"0001641172-25-002556","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoVibronix director Aurora Cassirer resigns effective April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cassirer resigned from the board and all committees (audit, governance, compensation) immediately.","Resignation not due to any disagreement with the company on operations, policies, or practices.","No replacement announced; board size reduced by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171338,"accession_number":"0001493152-25-010269","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix UroShield study shows 86% fewer UTIs, 70% fewer blockages, cost savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["86% reduction in UTI incidence and 70% fewer catheter blockages in independent study published in Australian and New Zealand Continence Journal.","82.8% less bladder irrigations and 52.3% fewer catheter changes reported with UroShield use.","Resource costs reduced by 63.5% over 5 months, easing nursing workload and lowering healthcare expenses.","CEO Brian Murphy highlighted improved patient comfort and reduced catheter-related interventions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171337,"accession_number":"0001493152-25-010040","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"NanoVibronix announces 1-for-11 reverse stock split effective March 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-11 ratio; shares outstanding drop from 8,716,327 to ~792,394.","Effective 4:05 p.m. ET on March 13, 2025; split-adjusted trading starts March 14, 2025 on Nasdaq.","No fractional shares issued; fractional shares rounded up to nearest whole share.","CUSIP changes to 63008J702; trading symbol remains NAOV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171336,"accession_number":"0001493152-25-008116","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoVibronix stockholders approve reverse stock split (1:2 to 1:11) and warrant issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved: 1,560,759 for, 674,302 against; board may set ratio between 1-for-2 and 1-for-11.","Issuance of shares underlying warrants from Jan 7 Exchange Agreement approved: 417,111 for, 290,431 against, with 1,528,273 broker non-votes.","Adjournment proposal approved but not needed as sufficient votes existed for both proposals.","Record date Jan 17, 2025; 6,138,028 shares outstanding; 2,242,618 votes present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171335,"accession_number":"0001493152-25-006855","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","3.03","5.02","5.03","7.01","9.01"],"status":"ready","headline":"NanoVibronix completes reverse merger with ENvue; ENvue holders to own 85% post-conversion","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed merger with ENvue Medical on Feb 14, 2025; issued 1,734,995 common shares (19.9% pre-merger) and 57,720 Series X Preferred (convertible 1,000:1, subject to stockholder approval).","Upon Series X conversion, ENvue holders would own 85% of common stock; existing NAOV holders would own 15%.","Three directors resigned; Doron Besser (ENvue CEO) and Zeev Rotstein appointed to board; Rotstein named to audit committee.","Issued $500K senior convertible debenture (8% interest, conversion price $0.4446 with floor $0.0889) to institutional investor.","Stockholder meeting to be called to approve Series X conversion, new incentive plan (10% of fully-diluted equity), and charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171334,"accession_number":"0001493152-25-001116","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"NanoVibronix exchanges $1.47 strike warrant for 456k shares and warrants at $0.62088","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 456,478 shares, warrant for 1,744,186 shares at $0.62088, and pre-funded warrant for 1,959,447 shares.","Old Series A-1 warrant ($1.47 strike) cancelled; new warrant subject to stockholder approval, 5.5-year term.","Exchange exempt under Section 3(a)(9); securities are unregistered and restricted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171333,"accession_number":"0001493152-25-000385","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NanoVibronix completes UroShield pilot study; Nasdaq panel grants limited extension with conditions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed pilot phase of UroShield RCT at Univ. of Michigan; full trial to begin in 2025.","Pilot focused on nursing home residents, studying reduction of UTIs, catheter blockages and pain.","Nasdaq panel granted extension until March 31, 2025 to meet bid price and equity rules.","Conditions: stockholder approval for reverse split by Feb 27, 2025; effect split and show $1.00 bid for 10 consecutive days.","Must also demonstrate compliance with $2.5M stockholders' equity requirement; delisting risk remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188329,"accession_number":"0001493152-24-051047","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NanoVibronix stockholders approve 2024 Long-Term Incentive Plan and elect eight directors at annual meeting.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2024 Long-Term Incentive Plan with 635,057 for, 262,753 against, 2,012 abstentions, and 1,146,998 broker non-votes.","Eight directors elected: Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, Harold Jacob, Thomas Mika, Brian Murphy, Maria Schroeder, each receiving 668,461–685,652 for votes.","Ratification of Zwik CPA as auditor for FY2024 passed with 2,006,926 for, 25,623 against, 14,271 abstentions.","Advisory vote on executive compensation approved: 629,513 for, 265,874 against, 4,435 abstentions, 1,146,998 broker non-votes.","Adjournment proposal approved (1,656,819 for, 376,540 against) but not needed as meeting proceeded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188328,"accession_number":"0001493152-24-050712","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix furnishes annual meeting presentation with no disclosed material updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Brian Murphy presented at the Dec 19, 2024 annual meeting; materials furnished via Form 8-K.","No specific financial or operational figures are provided in the filing excerpt.","The presentation is furnished under Regulation FD and not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188327,"accession_number":"0001493152-24-049645","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NanoVibronix renews PainShield distribution deal with Ultra Pain; secures $12M minimum purchase commitment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Renewed exclusive distribution agreement with Ultra Pain Products for PainShield for five years.","Minimum purchase commitment valued at $12 million over the term of the agreement.","CEO Brian Murphy highlighted UPPI's growth and transition into manufacturing as key factors.","PainShield is a non-opioid portable ultrasound device for pain management and injury recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188326,"accession_number":"0001493152-24-047385","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NanoVibronix receives Nasdaq equity deficiency notice; equity of $1.872M below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Nov 19, 2024, Nasdaq notified NanoVibronix it failed the $2.5M stockholders' equity rule based on $1.872M as of Sep 30, 2024.","This adds to an existing bid price deficiency; both will be considered at the upcoming Nasdaq Hearings Panel hearing.","The Company will present a compliance plan and request an extension, but continued listing is not assured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188325,"accession_number":"0001493152-24-040934","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NanoVibronix receives Nasdaq delisting notice for failure to meet $1.00 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to regain compliance with $1.00 minimum bid price by Oct 7, 2024; Nasdaq notified Oct 8.","Company will request a hearing before Nasdaq Hearings Panel, which will stay delisting action pending hearing.","No guarantee that the Panel will grant continued listing or an extension of time to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188324,"accession_number":"0001493152-24-040311","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"NanoVibronix sets 2024 annual meeting for Dec 19; shareholder proposal deadline Oct 17","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Annual Meeting of Stockholders scheduled for Thursday, December 19, 2024.","Record date for voting is close of business on October 28, 2024.","Deadline for Rule 14a-8 shareholder proposals and director nominations is October 17, 2024.","Universal proxy rule compliance notice also due by October 17, 2024.","Meeting date changed by more than 30 days from prior year's anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204803,"accession_number":"0001493152-24-038139","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NanoVibronix enters new employment agreements with CEO and CFO through Aug 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brian Murphy new agreement: $321K base salary, up to $100K annual bonus, effective Sept 20, 2024 to Aug 31, 2025.","CFO Stephen Brown new agreement: $267.5K base salary, up to $50K annual bonus, same term as CEO.","Both agreements allow termination on 90 days notice; severance of 12 months base plus ancillary payments if terminated without cause or for good reason.","CEO and CFO eligible for future stock option grants under a new equity incentive plan to be adopted.","Existing 2022 employment agreements were terminated upon effectiveness of new agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221656,"accession_number":"0001493152-24-020229","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix reports record Q1 revenue of $921K; operating loss $568K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $921K, largest Q1 ever; operating loss $568K.","Cash $2.7M, inventory $2.6M; balance sheet strong.","GSA contract for VA sales effective May 1, 2024, expected to accelerate adoption.","UroShield RCT study at University of Michigan begins pilot phase (up to 30 patients).","PainShield adoption growing in VA and workers' comp markets."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":921000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221655,"accession_number":"0001493152-24-014611","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NanoVibronix receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on April 10, 2024: common stock failed $1.00 minimum bid for 30 consecutive business days.","Compliance period of 180 calendar days until October 7, 2024 to regain listing requirement.","To cure, closing bid price must be $1.00 or more for at least 10 consecutive business days.","If not cured, may be eligible for additional 180-day period if other listing standards are met.","No immediate impact on trading; common stock continues to trade on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221654,"accession_number":"0001493152-24-014067","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix Q4 2023 revenue $1.2M record; CMS reimbursement still not approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2023 revenue of $1.2M (record quarter); loss from operations of $702K.","Cash of $3.3M, inventory $2.7M; raised $4.2M net in Q3 2023.","CMS reimbursement for PainShield still not approved; efforts continue.","University of Michigan to initiate UroShield RCT (pilot 30, full study 300+).","Selected engineering partner for next-gen product development expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241200,"accession_number":"0001493152-24-011629","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"NanoVibronix signs $1.1M R&D deal with Veranex for next-gen UroShield, PainShield","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into agreement with Veranex for R&D services for next-gen UroShield and PainShield; term ~50 weeks; fee up to ~$1.1M.","Fee payable monthly, due 45 days after invoice; late fee 1.5% per month; Veranex may suspend services if payment not made.","Either party may terminate on 60 days' notice; Veranex can also terminate for repeated late payments or relationship issues.","CEO Brian Murphy stated partnership aims to add therapeutic functionality and reduce cost of goods; press release dated March 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241199,"accession_number":"0001493152-24-002728","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NanoVibronix cancels Special Meeting of Shareholders scheduled for Jan 25, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company had previously announced Special Meeting for January 25, 2024, but has now cancelled it.","No reason for the cancellation was provided in the filing.","The meeting was to be held under the company's proxy solicitation; cancellation may affect any proposed actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258667,"accession_number":"0001493152-23-044397","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"NanoVibronix dismisses Marcum, appoints Zwick as auditor; going concern doubt noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Marcum LLP as independent auditor effective Dec 7, 2023; engaged Zwick CPA PLLC effective immediately.","Marcum's reports for FY2021 and FY2022 contained a going concern explanatory paragraph.","Material weaknesses in internal control over financial reporting were identified for both years.","No disagreements with Marcum on accounting principles, audit scope, or financial statement disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258666,"accession_number":"0001493152-23-043577","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NanoVibronix cancels 102,038 underwater stock options for $1 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cancelled 102,038 options with exercise prices from $8.94 to $51.40 per share.","Nine optionholders (including Aurora Cassirer, Brian Murphy) each received $1.00.","Options were deeply underwater; net value $0.00 as of effective date.","Effective November 29, 2023; no further rights or obligations remain.","Nominal $9 total payout eliminates potential dilution from these options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258665,"accession_number":"0001493152-23-042857","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix signs research agreement with University of Michigan for RCT of UroShield","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["UroShield study targets nursing home residents; aims to reduce UTIs, catheter blockages, and pain.","Pilot of 20 patients precedes full study of over 300 patients; expected to start H1 2024.","Positive results could support application to FDA for permanent clearance; currently under Enforcement Discretion.","Study led by Center for Research and Innovations in Special Populations (CRIISP) at University of Michigan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258664,"accession_number":"0001493152-23-042203","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NanoVibronix regains Nasdaq compliance by meeting $2.5M equity minimum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq confirmation on Nov 20, 2023 that it meets minimum stockholders' equity of $2.5M.","Previously disclosed deficiency on May 23, 2023 with equity of ~$2.2M; now resolved.","Listing matter closed; no further action required per Nasdaq Staff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258663,"accession_number":"0001493152-23-040784","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix posts $458K Q3 revenue; CMS reimbursement request not approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2023 revenue of $458,000; operating loss of $670,000; year-to-date revenue up 22%, operating loss reduced ~20%.","Raised $4.2M net from securities sales; cash & receivables $3.8M, inventory >$3.1M.","UK NHS supply contract and Drug Tariff reimbursement effective Nov 1; UK distributor Peak Medical pursuing opportunities.","Added Mio-Guard as exclusive distributor for Sports segment; VA and Workers Comp channels progressing.","CMS denied full reimbursement again after August 2023 notification; company awaiting response after meeting with CMS leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258662,"accession_number":"0001493152-23-039650","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix UroShield products now on NHS Drug Tariff; stocking order received","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UroShield actuators eligible for full NHS reimbursement effective Nov 1, 2023.","Received stocking order from UK distributor Peak Medical Limited; products shipped.","Clinicians can prescribe via Drug Tariff or NHS procurement contract; patients no longer pay.","CEO states increased demand since Nov 1; production ramped to meet expected growth.","Partner Peak Medical will educate healthcare providers and accept orders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275977,"accession_number":"0001493152-23-033834","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix receives NHS Drug Tariff approval for UroShield actuators; contract extended to 4 years","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NHS Drug Tariff approval enables full reimbursement of UroShield actuators starting November 1, 2023 for clinicians to prescribe.","NHS Supply Chain contract extended up to four years via UK distribution partner Peak Medical Limited.","CEO Brian Murphy: reimbursement removes critical barrier; expects increased unit sales and production to meet demand.","UroShield is used for preventing Catheter-Associated Urinary Tract Infections (CAUTIs) in patients with indwelling catheters.","Patients can now receive full UroShield system with NHS covering cost, not patient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275976,"accession_number":"0001493152-23-031741","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix to present positive UroShield study at ICS 2023; reduces CAUTI and blockages","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Sandra Wilks to present UroShield study at ICS 2023 in Toronto on September 27.","University of Southampton study shows UroShield reduces catheter-associated urinary tract infections and blockages.","Study suggests UroShield may promote healthy urinary microbiome and reduce antibiotic use.","UroShield uses low-frequency ultrasound to prevent bacterial biofilm on catheters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275975,"accession_number":"0001493152-23-031487","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"NanoVibronix raises ~$5M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,906,977 shares (or equivalents) plus A-1 and A-2 warrants each for up to 2,906,977 shares at $1.72/unit.","A-1 warrants exercisable at $1.47/share for 5.5 years; A-2 warrants identical with 13-month term.","Gross proceeds ~$5M, net ~$4.3M after fees; closing expected Sept 1, 2023.","Proceeds for general corporate purposes including development, sales/marketing, and potential acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275974,"accession_number":"0001493152-23-030624","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NanoVibronix reports positive UroShield study; 1/3 of patients saw fewer blockages","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately one-third of patients reported reduction in catheter blockages and need for unscheduled changes.","Qualitative data showed favorable opinions from majority of participants in the independent study.","Study published on ScienceDirect; investigated UroShield's effect on CAUTI and catheter blockage.","CEO highlights market opportunities and need for alternatives to antibiotics in long-term catheter care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275973,"accession_number":"0001493152-23-030531","cik":1326706,"company_name":"ENvue Medical, Inc.","ticker":"FEED","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS denies Medicare/Medicaid reimbursement for NanoVibronix PainShield device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS concluded PainShield does not fall within DMEPOS benefit category, so not reimbursable under Medicare/Medicaid.","CEO Brian Murphy says company plans to develop action plan and resubmit application for additional CMS review.","Company continues distribution in workers' comp, personal injury, and VA markets while addressing CMS concerns.","NanoVibronix believes PainShield benefits over 150M Medicare/Medicaid patients but faces reimbursement setback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5469868.727758077,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-29T23:59:59+00:00|275973"}